About this Journal Submit a Manuscript Table of Contents
Arthritis
Volume 2013 (2013), Article ID 818037, 10 pages
http://dx.doi.org/10.1155/2013/818037
Clinical Study

Determination of the Diagnostic Values of Asymmetric Dimethylarginine as an Indicator for Evaluation of the Endothelial Dysfunction in Patients with Rheumatoid Arthritis

1Department of Rheumatology, University Clinical Centre, Skopje, Macedonia
2Department of Hematology, University Clinical Centre, Skopje, Macedonia
3Department of Preclinic Pharmacology, University Clinical Centre, Skopje, Macedonia
4Department of Physiology, University Clinical Centre, Skopje, Macedonia
5Institute of Preclinic Biochemistry, University Clinical Centre, Skopje, Macedonia

Received 4 March 2013; Revised 19 April 2013; Accepted 19 April 2013

Academic Editor: Pierre Youinou

Copyright © 2013 Dejan Spasovski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. J. Watson, T. Rhodes, and H. A. Guess, “All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database,” The Journal of Rheumatology, vol. 30, no. 6, pp. 1196–1202, 2003. View at Scopus
  2. D. H. Solomon, E. W. Karlson, E. B. Rimm et al., “Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis,” Circulation, vol. 107, no. 9, pp. 1303–1307, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. I. Del Rincón, D. H. O'Leary, G. L. Freeman, and A. Escalante, “Acceleration of atherosclerosis during the course of rheumatoid arthritis,” Atherosclerosis, vol. 195, no. 2, pp. 354–360, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Ross, “Atherosclerosis—an inflammatory disease,” The New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Maradit-Kremers, P. J. Nicola, C. S. Crowson, K. V. Ballman, and S. E. Gabriel, “Cardiovascular death in rheumatoid arthritis: a population-based study,” Arthritis & Rheumatism, vol. 52, no. 3, pp. 722–732, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Del Rincon, K. Williams, M. P. Stern, G. L. Freeman, and A. Escalante, “High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors,” Arthritis & Rheumatism, vol. 44, pp. 2737–2745, 2001.
  7. I. Del Rincón, G. L. Freeman, R. W. Haas, D. H. O'Leary, and A. Escalante, “Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis,” Arthritis & Rheumatism, vol. 52, no. 11, pp. 3413–3423, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Van Doornum, G. McColl, and I. P. Wicks, “Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?” Arthritis & Rheumatism, vol. 46, no. 4, pp. 862–873, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. M. A. Gonzalez-Gay, C. Gonzalez-Juanatey, A. Piñeiro, C. Garcia-Porrua, A. Testa, and J. Llorca, “High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis,” The Journal of Rheumatology, vol. 32, no. 7, pp. 1219–1223, 2005. View at Scopus
  10. S. Hänsel, G. Lässig, F. Pistrosch, and J. Passauer, “Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity,” Atherosclerosis, vol. 170, no. 1, pp. 177–180, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Vaudo, S. Marchesi, R. Gerli et al., “Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity,” Annals of the Rheumatic Diseases, vol. 63, no. 1, pp. 31–35, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. P. H. Dessein, B. I. Joffe, and S. Singh, “Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis,” Arthritis Research & Therapy, vol. 7, no. 3, pp. R634–R643, 2005. View at Scopus
  13. S. M. Bode-Böger, F. Scalera, J. T. Kielstein et al., “Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease,” Journal of the American Society of Nephrology, vol. 17, no. 4, pp. 1128–1134, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. J. T. Kielstein, S. R. Salpeter, S. M. Bode-Boeger, J. P. Cooke, and D. Fliser, “Symmetric dimethylarginine (SDMA) as endogenous marker of renal function—a meta-analysis,” Nephrology Dialysis Transplantation, vol. 21, no. 9, pp. 2446–2451, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Wanby, T. Teerlink, L. Brudin et al., “Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population,” Atherosclerosis, vol. 185, no. 2, pp. 271–277, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Murray-Rust, J. Leiper, M. McAlister, et al., “Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase,” Nature Structural Biology, vol. 8, pp. 679–683, 2001.
  17. C. T. L. Tran, J. M. Leiper, and P. Vallance, “The DDAH/ADMA/NOS pathway,” Atherosclerosis Supplements, vol. 4, no. 4, pp. 33–40, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Vallance and J. Leiper, “Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 6, pp. 1023–1030, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Ito, P. S. Tsao, S. Adimoolam, M. Kimoto, T. Ogawa, and J. P. Cooke, “Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase,” Circulation, vol. 99, no. 24, pp. 3092–3095, 1999. View at Scopus
  20. J. Leiper, J. Murray-Rust, N. McDonald, and P. Vallance, “S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 21, pp. 13527–13532, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. P. H. J. Remans, M. van Oosterhout, T. J. M. Smeets et al., “Intracellular free radical production in synovial T lymphocytes from patients with rheumatoid arthritis,” Arthritis & Rheumatism, vol. 52, no. 7, pp. 2003–2009, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Kaur and B. Halliwell, “Evidence for nitric oxide-mediated oxidative damage in chronic inflammation. Nitrotyrosine in serum and synovial fluid from rheumatoid patients,” FEBS Letters, vol. 350, no. 1, pp. 9–12, 1994. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Hürlimann, A. Forster, G. Noll et al., “Anti-tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis,” Circulation, vol. 106, no. 17, pp. 2184–2187, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. R. H. Böger, K. Sydow, J. Borlak et al., “LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases,” Circulation Research, vol. 87, no. 2, pp. 99–105, 2000. View at Scopus
  25. J. Middleton, L. Americh, R. Gayon et al., “Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky,” Arthritis Research and Therapy, vol. 6, no. 2, pp. 60–72, 2004. View at Scopus
  26. R. H. Böger, S. M. Bode-Böger, P. S. Tsao, P. S. Lin, J. R. Chan, and J. P. Cooke, “An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes,” Journal of the American College of Cardiology, vol. 36, no. 7, pp. 2287–2295, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. L. J. Millatt, G. S. J. Whitley, D. Li et al., “Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension,” Circulation, vol. 108, no. 12, pp. 1493–1498, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. E. B. Marliss, S. Chevalier, R. Gougeon et al., “Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover,” Diabetologia, vol. 49, no. 2, pp. 351–359, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Hedner, A. Himmelmann, and L. Hansson, “Homocysteine and ADMA—emerging risk factors for cardiovascular disease?” Blood Pressure, vol. 11, no. 4, pp. 197–200, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. V. P. Valkonen, J. Laakso, H. Päivä, et al., “Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels?” Atherosclerosis Supplements, vol. 4, pp. 19–22, 2003.
  31. K. Sydow, B. Hornig, N. Arakawa et al., “Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA,” Vascular Medicine, vol. 9, no. 2, pp. 93–101, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Gorenflo, C. Zheng, E. Werle, W. Fiehn, and H. E. Ulmer, “Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension,” Journal of Cardiovascular Pharmacology, vol. 37, no. 4, pp. 489–492, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. W. Z. Zhang, K. Venardos, J. Chin-Dusting, and D. M. Kaye, “Adverse effects of cigarette smoke on no bioavailability: role of arginine metabolism and oxidative stress,” Hypertension, vol. 48, no. 2, pp. 278–285, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Y. Lin, A. Ito, T. Asagami et al., “Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase,” Circulation, vol. 106, no. 8, pp. 987–992, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. F. Mittermayer, K. Krzyzanowska, and M. Wolzt, “Asymmetric dimethylarginine (ADMA): a cardiovascular risk factor,” Wiener Klinische Wochenschrift, vol. 120, no. 15-16, pp. 462–466, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. F. C. Arnett, S. M. Edworthy, D. A. Bloch et al., “The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis,” Arthritis & Rheumatism, vol. 31, no. 3, pp. 315–324, 1988. View at Scopus
  37. A. M. Van Gestel, M. L. L. Prevoo, M. A. van 'T Hof, M. H. van Rijswijk, L. B. A. van de Putte, and P. L. C. M. van Riel, “Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis,” Arthritis & Rheumatism, vol. 39, no. 1, pp. 34–40, 1996. View at Scopus
  38. M. L. L. Prevoo, M. A. van 'T Hof, H. H. Kuper, M. A. van Leeuwen, L. B. A. van de Putte, and P. L. C. M. van Riel, “Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis,” Arthritis & Rheumatism, vol. 38, no. 1, pp. 44–48, 1995. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Balsa, L. Carmona, I. González-Álvaro, M. A. Belmonte, X. Tina, and R. Sanmartí, “Value of DAS-28 and DAS 28-3 as compared to ACR-defined remission in rheumatoid arthritis,” The Journal of Rheumatology, vol. 31, pp. 40–46, 2004.
  40. M. L. L. Prevoo, A. M. van Gestel, M. A. van 'T Hof, M. H. van Rijswijk, L. B. A. van de Putte, and P. L. C. M. van Riel, “Remission in a prospective study of patients with rheumatoid arthritis. American rheumatism association preliminary remission criteria in relation to the disease activity score,” British Journal of Rheumatology, vol. 35, no. 11, pp. 1101–1105, 1996. View at Scopus
  41. G. Vaudo, S. Marchesi, R. Gerli et al., “Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity,” Annals of the Rheumatic Diseases, vol. 63, no. 1, pp. 31–35, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Surdacki, J. Martens-Lobenhoffer, A. Wloch et al., “Plasma asymmetric dimethylarginine is related to anticitrullinated protein antibodies in rheumatoid arthritis of short duration,” Metabolism, vol. 58, no. 3, pp. 316–318, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Turiel, L. Tomasoni, S. Sitia et al., “Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis,” Cardiovascular Therapeutics, vol. 28, no. 5, pp. e53–e64, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. F. Khan, B. Galarraga, and J. J. F. Belch, “The role of endothelial function and its assessment in rheumatoid arthritis,” Nature Reviews Rheumatology, vol. 6, no. 5, pp. 253–261, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. M. E. Widlansky, N. Gokce, J. F. Keaney Jr., and J. A. Vita, “The clinical implications of endothelial dysfunction,” Journal of the American College of Cardiology, vol. 42, no. 7, pp. 1149–1160, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Wong, L. Toh, A. Wilson et al., “Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation,” Arthritis & Rheumatism, vol. 48, no. 1, pp. 81–89, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Gonzalez-Juanatey, A. Testa, A. Garcia-Castelo et al., “HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis,” American Journal of Medicine, vol. 114, no. 8, pp. 647–652, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Bergholm, M. Leirisalo-Repo, S. Vehkavaara, S. Mäkimattila, M. R. Taskinen, and H. Yki-Järvinen, “Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 10, pp. 1637–1641, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. G. Vaudo, S. Marchesi, R. Gerli et al., “Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity,” Annals of the Rheumatic Diseases, vol. 63, no. 1, pp. 31–35, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. K. M. Mäki-Petäjä, F. C. Hall, A. D. Booth et al., “Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-α therapy,” Circulation, vol. 114, no. 11, pp. 1185–1192, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. D. Datta, W. R. Ferrell, R. D. Sturrock, S. T. Jadhav, and N. Sattar, “Inflammatory suppression rapidly attenuates microvascular dysfunction in rheumatoid arthritis,” Atherosclerosis, vol. 192, no. 2, pp. 391–395, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. C. Gonzalez-Juanatey, A. Testa, A. Garcia-Castelo, C. Garcia-Porrua, J. Llorca, and M. A. Gonzalez-Gay, “Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor α antibody,” Arthritis Care and Research, vol. 51, no. 3, pp. 447–450, 2004. View at Scopus
  53. D. Hürlimann, A. Forster, G. Noll et al., “Anti-tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis,” Circulation, vol. 106, no. 17, pp. 2184–2187, 2002. View at Publisher · View at Google Scholar · View at Scopus